We are proud of the work that we do at Advanta. Even more so, we’re happy to help our clients continue to get the exposure they need and deserve. Some of the clients we’ve worked with and continue to, have had some very impressive media coverage. Please see below for our clients in the news.
Genome Profiling and Fox Chase Cancer Center will collaborate to identify a novel immune system epigenetic biomarker, dubbed EpiMarker, which if successful, will be used to help predict which lung cancer patients are likely to respond to a checkpoint inhibitor therapy known as anti-PD1 antibody.
